Platinum open access journal
pISSN 2466-0493 eISSN 2466-054X
Indexed in MEDLINE, SCIE, Scopus, DOAJ and more
    Korean J Urol. 2006 Oct;47(10):1041-1045. Korean.
    Published online Oct 31, 2006.
    https://doi.org/10.4111/kju.2006.47.10.1041
    Copyright © 2006 The Korean Urological Association
    Original Article

    Urinary Survivin Test Compared to the Nuclear Matrix Protein (NMP)-22 Test and Urine Cytology for the Diagnosis of Bladder Cancer

    Sang Hoon Chang, Young Ho Kim and Min Eui Kim
      • Department of Urology, Soonchunhyang University Hospital, Bucheon, Korea.
    • Corresponding author (Email: mekim@schbc.ac.kr )
    Received May 15, 2006; Accepted July 21, 2006.

    Abstract

    Purpose

    The aim of this study was to compare the sensitivity and specificity of the urinary survivin test for the diagnosis of bladder cancer with the nuclear matrix protein (NMP)-22 test and the urine cytology, and we wanted to correlate survivin with the tumor stage and grade.

    Materials and Methods

    Between October 2002 and March 2004, voided urine samples were obtained from 41 patients with bladder cancer and also from 36 controls who had no evidence of bladder cancer. The urinary survivin and NMP-22 levels were measured using a DuoSet IC ELISA kit and an automated chemiluminescent assay system. The results were compared with the cytologic results and the pathologic findings.

    Results

    The comparative results showed the higher sensitivity for the urinary survivin test (78.0%) and the NMP-22 test (75.6%) than for the urine cytology (65.8%) for the detection of bladder cancer. The specificity of urinary survivin (86.1%) and urine cytology (97.2%) were higher than that for the NMP-22 test (66.6%). Measuring the urinary survivin level was a more accurate test than the urinary NMP-22 test and the urine cytology for the detection of lower grade and superficial bladder cancer.

    Conclusions

    The urinary survivin test was superior to urine cytology for sensitivity and specificity, and these two parameters of the urinary survivin test were higher than those of the NMP-22 test. Especially, the urinary survivin test is an accurate diagnostic test for superficial and lower grade bladder tumor. Our results suggested that the urinary survivin test appears to be a reliable diagnostic test to identify patients with bladder cancer.

    Keywords
    Bladder cancer; Survivin; Nuclear matrix protein 22; Urine; Cytology

    Tables

    Table 1
    Overall results of the urinary survivin test, the NMP-22 test and the urine cytology

    Table 2
    The urinary survivin test, NMP-22 test and urine cytology for detecting urothelial carcinoma of the bladder according to the tumor stage

    Table 3
    The urinary survivin test, NMP-22 test and urine cytology for detecting of urothelial carcinoma of the bladder according to the tumor grade

    Table 4
    The overall sensitivity of the urinary survivin test, the survivin test+the NMP-22 test and the survivin test+the urine cytology

    References

      1. Kwon DH, Hong SJ. The clinical utility of BTA TRAK, BTA stat, NMP22 and urine cytology in the diagnosis of bladder cancer: a comparative study. Korean J Urol 2003;44:721–726.
      1. Park JO, Moon DG, Cheon J, Kim JJ, Yoon DK. Urinary NMP (nuclear matrix protein) 22 in screening and post-treatment follow-up bladder cancer. Korean J Urol 1999;40:551–556.
      1. Shariat SF, Casella R, Khoddami SM, Hernandez G, Sulser T, Gasser TC, et al. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 2004;171:626–630.
      1. Kim JM, Lee KW, Kim YH, Park SK, Lee YK, Kim ME. Expression of urinary survivin as a new tumor marker for the detection of bladder cancer. Korean J Urol 2004;45:1219–1223.
      1. Fuessel S, Kueppers B, Ning S, Kotzsch M, Kraemer K, Schmidt U, et al. Systematic in vitro evaluation of survivin directed antisense oligodeoxynucleotides in bladder cancer cells. J Urol 2004;171:2471–2476.
      1. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396:580–584.
      1. Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C, et al. Analysis of human transcriptomes. Nature Genet 1999;23:387–388.
      1. Konno R, Yamakawa H, Utsunomiya H, Ito K, Sato S, Yajima A. Expression of survivin and Bcl-2 in the normal human endometrium. Mol Hum Reprod 2000;6:529–534.
      1. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917–921.
      1. Swana HA, Grossman D, Anthony JN, Weiss RM, Altieri DC. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med 1999;341:452–453.
      1. Hausladen DA, Wheeler MA, Altieri DC, Colberg JW, Weiss RM. Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome. J Urol 2003;170:230–234.
      1. Ku JH, Kwak C, Lee HS, Park HK, Lee ES, Lee SE. Expression of survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder. J Urol 2004;171:631–635.
      1. Garcia I, Martinou I, Tsujimoto Y, Martinou JC. Prevention of programmed cell death of sympathetic neurons by the bcl-2 proto-oncogene. Science 1992;258:302–304.
      1. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998;58:5315–5320.
      1. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001;285:324–328.
      1. Schultz IJ, Kiemeney LA, Witjes JA, Schalken JA, Willems JL, Swinkels DW, et al. Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. Anticancer Res 2003;23:3327–3331.
      1. Miller TE, Beausang LA, Winchell LF, Lidgard GP. Detection of nuclear matrix proteins in serum from cancer patients. Cancer Res 1992;52:422–427.
      1. Keesee SK, Briggman JV, Thill G, Wu YJ. Utilization of nuclear matrix proteins for cancer diagnosis. Crit Rev Eukaryot Gene Expr 1996;6:189–214.
    Cited by
    Crossref 2
    Google Scholar 
    Scopus 4
    MeSH Terms
    Diagnosis*
    Diagnostic Tests, Routine
    Enzyme-Linked Immunosorbent Assay
    Humans
    Luminescent Measurements
    Nuclear Matrix*
    Sensitivity and Specificity
    Urinary Bladder Neoplasms*
    Urinary Bladder*
    Metrics
    Share
    Tables
    slide
    slide
    slide
    slide

    1 / 4

    PERMALINK